

-continued

```

<223> OTHER INFORMATION: Human minimal bile salt export pump (ABCB11)
gene promoter

<400> SEQUENCE: 7

ttccaagca cactctgtgt ttgggggttat tgctctgagt atgtttctcg tatgtcactg      60
aactgtgctt gggctgcctt tagggacatt gatccttagg caaatagata atgttcttga      120
aaaagtttga attctgttca gtgctt                                           145

<210> SEQ ID NO 8
<211> LENGTH: 145
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Mouse minimal Bile Salt export pump (ABCB11)
gene promoter

<400> SEQUENCE: 8

ggttcctgct ttgagtatgt tcgaccttct ctctcatgtc actgaactgt gctagatctg      60
gactttaggc cattgacctt taagcaaata gatagtgttc ttaaaaaagc ctgatttctg      120
ttcaatgctt tattaccatg aaaac                                           145

<210> SEQ ID NO 9
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Forward alpha-1-anti-trypsin promoter primer

<400> SEQUENCE: 9

ttgctcctcc gataactggg                                           20

<210> SEQ ID NO 10
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Reverse alpha-1-anti-trypsin promoter primer

<400> SEQUENCE: 10

ccctgtcttc gtccgtattt                                           20

```

1.-16. (canceled)

17. A nucleic acid construct comprising a transgene encoding MDR3 isoform A, said transgene is the sequence SEQ ID NO: 1 or a sequence having at least 90% of identity with SEQ ID NO: 1.

18. The nucleic acid construct of claim **17** further comprising a liver-specific promoter, preferably an alpha-1-antitrypsin promoter or a bile salt-inducible promoter.

19. The nucleic acid construct of claim **17** further comprising a polyadenylation signal sequence, notably a synthetic polyadenylation signal sequence having sequence SEQ ID NO: 3.

20. The nucleic acid construct according to claim **17** further comprising 5'ITR and a 3'ITR sequences.

21. The nucleic acid construct according to claim **17** comprising nucleic acid sequence SEQ ID NO: 4 or a nucleic acid sequence having at least 90% of identity with SEQ ID NO: 4.

22. An expression vector comprising a nucleic acid construct according to claim **17**.

23. The expression vector of claim **22** wherein said vector is a viral vector.

24. A viral particle comprising a nucleic acid construct according to claim **17** or an expression vector comprising such a nucleic acid construct.

25. An AAV particle comprising a nucleic acid construct according to claim **17** or an expression vector comprising such a nucleic acid construct.

26. A host cell comprising a nucleic acid construct according to claim **17** or an expression vector comprising such a nucleic acid construct, or a host cell transduced with a viral particle comprising such a nucleic acid construct or such an expression vector.

27. A pharmaceutical composition comprising a nucleic acid construct according to claim **17**, and a pharmaceutically acceptable excipient.